-

The Law Offices of Frank R. Cruz Announces Investigation of Orphazyme A/S (ORPH) on Behalf of Investors

Investors with losses exceeding $500,000 are encouraged to contact the firm

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Orphazyme A/S ("Orphazyme" or the "Company") (NASDAQ: ORPH) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

Orphazyme is a biopharmaceutical company that develops therapies for the treatment of neurodegenerative orphan diseases. Its leading drug candidate is arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C ("NPC"), Amyotrophic Lateral Sclerosis ("ALS"), and Inclusion Body Myositis ("IBM").

In September 2020, Orphazyme completed its initial public offering (“IPO”), selling approximately 4 million American Depositary Shares (“ADSs” or “shares”) at $11.00 per share. The same month, the Company’s New Drug Application (“NDA”) for arimoclomol for NPC was accepted by the U.S. Food and Drug Administration (“FDA”).

On March 29, 2021, the Company disclosed in a press release "its phase 2/3 trial evaluating arimoclomol for the treatment of [IBM] . . . did not meet its primary and secondary endpoints."

On this news, the Company’s ADS price fell $3.59 per ADS, or 28.97%, to close at $8.80 per ADS on March 29, 2021, thereby injuring investors.

Then, on May 7, 2021, the Company disclosed in a press release "topline data from pivotal trial of arimoclomol in [ALS],” stating that the trial “did not meet its primary and secondary endpoints to show benefit in people living with ALS."

On this news, the Company’s ADS price fell $2.81 per ADS, or 32.83%, to close at $5.75 per ADS on May 7, 2021, thereby injuring investors.

Then, on June 18, 2021, the Company announced it had received a Complete Response Letter (“CRL”) from the FDA. Specifically, the FDA had rejected the arimoclomol NDA for NPC "based on needing additional qualitative and quantitative evidence to further substantiate the validity and interpretation" of certain data and "that additional data are needed to bolster confirmatory evidence beyond the single phase 2/3 clinical trial to support the benefit-risk assessment of the NDA."

On this news, the Company’s ADS price fell $7.23 per ADS, or 49.66%, to close at $7.33 per ADS on June 18, 2021, thereby injuring investors.

Finally, on June 21, 2021, Seeking Alpha reported that "Orphazyme [was] cut to sell at Guggenheim,” which noted that there is “little optionality left in the stock” “it might make sense to wind down the company."

On this news, the Company’s ADS price fell $0.81 per ADS, or 11.05%, to close at $6.52 per ADS on June 21, 2021, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Orphazyme securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

The Law Offices of Frank R. Cruz

NASDAQ:ORPH

Release Summary
The Law Offices of Frank R. Cruz Announces Investigation of Orphazyme A/S (ORPH) on Behalf of Investors
Release Versions
$Cashtags

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

Social Media Profiles
More News From The Law Offices of Frank R. Cruz

Deadline Alert: Nuscale Power Corporation Shareholders Have Until January 11, 2027 to Seek Lead Plaintiff Appointment in Securities Fraud Lawsuit, The Law Offices of Frank R. Cruz Notes

LOS ANGELES--(BUSINESS WIRE)--The deadline for Nuscale Power Corporation ("Nuscale" or the "Company") (NYSE: SMR) investors to seek appointment as lead plaintiff in a securities class action lawsuit is January 11, 2027. The lawsuit was filed on behalf of investors who purchased or otherwise acquired Nuscale Power Corporation securities from February 27, 2026 to September 10, 2026, inclusive. The Law Offices of Frank R. Cruz today reminded investors of the deadline in the case, Chiu-Yueh Chang v...

Deadline Alert: Portillo's Inc. Shareholders Have Until January 11, 2027 to Seek Lead Plaintiff Appointment in Securities Fraud Lawsuit, The Law Offices of Frank R. Cruz Notes

LOS ANGELES--(BUSINESS WIRE)--The deadline for Portillo's Inc. ("Portillo's" or the "Company") (NASDAQ: PTLO) investors to seek appointment as lead plaintiff in a securities class action lawsuit is January 11, 2027. The lawsuit was filed on behalf of investors who purchased or otherwise acquired Portillo's Inc. securities from September 19, 2023 to May 4, 2026, inclusive. The Law Offices of Frank R. Cruz today reminded investors of the deadline in the case, Wassel v. Portillo's Inc. et al., file...

Lost Money on Digital Turbine, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 35.8% Stock Decline

LOS ANGELES--(BUSINESS WIRE)--Digital Turbine, Inc. ("Digital Turbine" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Digital Turbine, Inc. (NASDAQ: APPS), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Digital Turbine, Inc. on November 9, 2026. If you...
Back to Newsroom